Collaborative and Other Relationships (Tables)

3 Months Ended

Mar. 31, 2022


	For the Three Months Ended March 31,
(In millions)	2022		2021
Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat	$	77.0	$	55.5
Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income	38.5		27.7
Total sales and marketing expense incurred by the Lecanemab Collaboration	15.9		5.7
Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income	8.0		2.9

A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:


	For the Three Months Ended March 31,
(In millions)	2022		2021
Total ADUHELM development expense	$	44.2	$	47.0
Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income	24.3		25.8
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement	95.0		111.8
Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income	50.9		60.3

A summary of development expense related to this collaboration is as follows:


	For the Three Months Ended March 31,
(In millions)	2022		2021
Total Denali collaboration development expense	$	14.9	$	15.4
Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income	8.9		9.2